A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Stopped Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient data to allow a registration study in PTCL (PXD101-CLN-19)

Conditions

• Cutaneous T-Cell Lymphoma
• Peripheral T-Cell Lymphoma
• Non-Hodgkin's Lymphoma

Interventions

• DRUG: belinostat

Sponsor

Valerio Therapeutics